Improving margins and cash flow support higher-quality growth; J.P. Morgan raises Estun target price to Rmb28

Overview

This report updates the model after Estun management's fireside chat, FY25 results, and the latest guidance. J.P. Morgan believes the company's gradual improvements in operating discipline, margin expansion, and cash generation are translating into stronger earnings visibility and a clearer path to higher-quality growth.

Core views

The core view is that Estun is no longer simply pursuing low-margin orders, but is repairing margins by exiting some low-margin automotive orders, turning around Cloos, improving inventory and receivables management, deleveraging, and tightening costs. On the growth side, the company is benefiting from domestic industrial robot market share gains, higher-end application penetration, a product mix shift toward medium and large robots, channel expansion, and internationalization. The report maintains an Overweight rating and raises the Jun-27 target price to Rmb28.

Analysis framework

The analysis is mainly based on information from management's fireside chat, actual FY25 performance, FY26 management guidance, J.P. Morgan's updated earnings model, comparisons with consensus expectations, and a FY27E P/E valuation framework. The report also examines order quality, gross margin, net margin, operating cash flow, debt burden, overseas business, and the competitive landscape.

Methodology notes

• Earnings forecastManagement communication and model update

  Incorporate FY25 results and the latest guidance into the forecast

  After the fireside chat, the report updates the model to incorporate selective project execution, product mix upgrades, deleveraging, cost control, and Cloos improvement into the FY26-FY28 forecast.

• Valuation methodsFY27E P/E valuation

  Derive the target price using FY27E earnings and a 75x P/E multiple

  The Jun-27 target price of Rmb28 is based on a 75x FY27E P/E, still below the historical cycle average of 125x.

• Scenario analysisPrudent net margin assumption

  Do not fully incorporate management's 5% NPM target

  Although management guides FY26 NPM to 5%, J.P. Morgan's model uses a more prudent 4.0% to reflect uncertainty in the macro environment and overseas exposure.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Estun Automation - A (002747.SZ)

  The report-covered company and the investment-rating subject

  Strengths

  Relatively strong vertically integrated capability, with in-house production of key components such as CNC systems, motion controllers, servos, machine vision, and small reducers; operating cash flow has improved, and the product mix is shifting toward medium/large and high-end robots.

  Weaknesses

  Large overseas exposure, net margin recovery still needs validation, and the systems integration/production line business previously weighed on margins.

  Comparison

  The report sees KUKA as a key competitor in the China market, especially in high-load scenarios and CATL-related projects; Inovance is also a domestic competitor in the high-end market.

  Risks

  Supply chain management, margins, sales growth, and a slower-than-expected recovery in the industrial robot cycle would affect the rating and target price.

• Cloos

  Estun-related business/integration target

  Strengths

  The turnaround is beginning to contribute to improvement, and there is a clear path for subsequent integration and cost structure optimization.

  Weaknesses

  It is still in the improvement phase, and sustainable profitability still needs to be validated.

  Comparison

  It is more of an important part of improving Estun's overall earnings quality than a major standalone valuation asset.

  Risks

  If integration progresses more slowly than expected, it could weigh on margin recovery.

• Estun Codroid

  Estun's sister company, involved in humanoid robot expansion

  Strengths

  Helps expand into the humanoid robotics field and enhances the product portfolio and long-term growth potential.

  Weaknesses

  The report does not provide specific financial contribution or commercialization timing.

  Comparison

  It mainly reflects product portfolio expansion rather than a core source of current earnings forecasts.

  Risks

  There is uncertainty around the rollout pace and profitability contribution of the humanoid robotics business.

Key data

• Current share priceRmb20.47As of 2026-04-10.
• Target priceRmb28.00Jun-27 target price; the previous Dec-26 target price was Rmb27.00.
• Implied upsidec.35%Based on the current price of Rmb20.47 and target price of Rmb28.
• FY27/28E forecast revisionUp to 20% higherThe updated forecast is about c.8% above consensus.
• Forecast-period profit CAGRc.110%Reflects margin recovery and improved operating quality.
• FY25 operating cash flowRmb507MMA record level, more than 10x PAT.
• FY26 revenue guidanceRmb6.0B, +20% Y/YManagement also guides robot shipments of 45,000 units.
• FY26 net profit guidancec.Rmb300MMManagement targets an NPM of 5%, while J.P. Morgan's model assumes FY26E NPM of 4.0%.
• 1Q26 sales growth expectationc.15% Y/YBroadly in line with year-to-date order trends.
• 1Q26 net profit expectationc.Rmb30MM, about +130% Y/YSupported by resilient demand, improved product mix, and cost control.
• Revenue CAGR forecast17%Revenue compound annual growth rate over the forecast period.
• 2026 self-owned export revenue expectationc.Rmb200MMThe Poland factory has started production and a local team has been established.
• Domestic market share targetc.10% to c.20%The company's long-term goal is to roughly double its domestic market share.

Impact & implications

If the company can continue improving order quality, stabilize gross margins, reduce financial burden, and drive growth in high-end robots and overseas business, earnings leverage and valuation re-rating room will increase. The investment implication is that the market should place greater emphasis on operating quality and cash flow improvement, rather than just short-term revenue growth.

Risks

• Supply chain management and margin performance below expectations.
• Sales growth below expectations.
• A slower-than-expected inflection in the industrial robot cycle.
• Fluctuations in raw material prices such as copper and aluminum may affect gross margins.
• Execution risks in overseas expansion and local team building.
• If exiting low-margin orders puts short-term pressure on revenue, the market may reassess growth quality.

What to watch

• Progress toward the FY26 revenue target of Rmb6.0B and robot shipment target of 45,000 units.
• Whether FY26 NPM can approach management's 5% target, or at least reach J.P. Morgan's 4.0% assumption.
• Actual 1Q26 performance of about Rmb30MM NPAT, about 30% GPM, and about 2% NPM.
• Progress on Cloos integration, profitability improvement, and cost structure optimization.
• Order and gross margin performance of medium and large six-axis robots, >100kg high-payload robots, and the iER intelligent robot series.
• Overseas revenue, Poland factory utilization, and local team expansion.
• Competitive outcomes against KUKA and Inovance in high-end automotive, lithium battery, electronics, and other scenarios.